Amphastar Pharmaceuticals (AMPH) Cost of Revenue (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Cost of Revenue of $100.8 million for Q1 2026, up 18.26% year-over-year from $85.3 million in Q1 2025, and up 3.5% quarter-over-quarter from $97.4 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Cost of Revenue (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Cost of Revenue history runs 14 years deep, the most recent figure standing at $100.8 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 18.26% year-over-year to $100.8 million; the TTM figure through Mar 2026 stood at $379.4 million (up 4.91% YoY), while the FY2025 annual figure was $363.8 million, up 1.6% from the prior year.
- Cost of Revenue for Q1 2026 stood at $100.8 million, up from $97.4 million in the prior quarter.
- The five-year high for Cost of Revenue was $100.8 million in Q1 2026, with the low at $60.1 million in Q2 2022.
- The 5-year median for Cost of Revenue is $82.0 million (2023), against an average of $80.4 million.
- The sharpest annual moves came in 2023 and 2025: Cost of Revenue gained 28.36% in 2023, then fell 2.44% in 2025.
- Amphastar Pharmaceuticals' Cost of Revenue stood at $63.9 million in 2022, then climbed by 28.36% to $82.0 million in 2023, then increased by 21.85% to $99.9 million in 2024, then decreased by 2.44% to $97.4 million in 2025, then climbed by 3.5% to $100.8 million in 2026.
- Business Quant data shows AMPH's Cost of Revenue at $100.8 million in Q1 2026, $97.4 million in Q4 2025, and $93.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 934.85 Mn | 644.73 Mn | 93.47 Mn | 90.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.43 Mn |
| Jun 30, 2026 | 90.43 Mn |
| Mar 31, 2026 | 100.85 Mn |
| Mar 31, 2026 | 100.85 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Sep 30, 2025 | 93.19 Mn |
| Sep 30, 2025 | 93.19 Mn |
| Jun 30, 2025 | 87.92 Mn |
| Jun 30, 2025 | 87.92 Mn |
| Mar 31, 2025 | 85.28 Mn |
| Mar 31, 2025 | 85.28 Mn |
| Dec 31, 2024 | 99.88 Mn |
| Dec 31, 2024 | 99.88 Mn |
| Sep 30, 2024 | 89.27 Mn |
| Sep 30, 2024 | 89.27 Mn |
| Jun 30, 2024 | 87.23 Mn |
| Jun 30, 2024 | 87.23 Mn |
| Mar 31, 2024 | 81.74 Mn |
| Mar 31, 2024 | 81.74 Mn |